has been the Chairman of the Board of the Company since January 2026. Mr. GAO joined China Resources in August 2007 and has successively worked for China Resources Enterprise Limited, the Company, China Resources Power Holdings Company Limited (a company listed on the Stock Exchange (stock code:836)) ("CR Power"), and China Resources (Holdings) Company Limited ("CRH"). Mr. GAO worked in the Company for nearly 10 years, possessing cross-disciplinary business management experience, and served as the chief financial officer of the Company from 2012 to 2020. From March 2020 to January 2026, he served as the deputy general manager of the Finance Department of CRH, the chief financial officer of CR Power，and the general manager of the Finance Department of CRH. Prior to joining China Resources, he worked in the National Audit Office（国家审计署） for many years. Mr. Gao holds a Bachelor's Degree and a Master's Degree in Economics from Dongbei University of Finance and Economics in China, and has been qualified as a China Certified Public Accountant and a Certified Internal Auditor.

has been the President of the Company since June 2024, and has been our Director since August 2024. Mr. LI joined CRH in August 1994, and successively worked in China Resources Head Office and China Resources Ng Fung Limited, etc. He held various management positions, from September 2011 to June 2024, he served as the assistant director and deputy director of the office of CRH, a vice general manager of China Resources Pharmaceutical Commercial Group Co., Ltd. (华润医药商业集团有限公司), and a vice general manager of China Resources Ng Fung Limited. Mr. LI holds a bachelor's degree of international trade from University of International Business and Economics.

served as the Vice President of the Company from November 2024 to July 2025，he has served as the senior management at the vice president level of the Company since July 2025, and has been appointed as a Director of the Company since August 2025. Prior to joining the Company, Mr. ZHOU served as deputy director of the Discipline Inspection and Supervision Department of CRH and deputy general manager of China Resources Vanguard Company Limited from August 2015 to January 2018; senior deputy director of the Discipline Inspection and Supervision Department of CRH and senior deputy general manager of China Resources Vanguard Company Limited from January 2018 to October 2018; and senior vice president of China Resources Power Holdings Company Limited (a company listed on the Stock Exchange (stock code: 00836)) from October 2018 to November 2024. Mr. ZHOU holds a bachelor's degree in laws from Jiangnan University in China.

was appointed as a non-executive Director in August 2025. Mr. ZHANG is currently a part-time external director of business units of China Resources (Holdings) Company Limited. He has more than 20 years of experience in corporate management, corporate mergers and acquisitions and asset management. He previously served as minister of department of business administration, assistant to president and deputy general manager of San Jiu Enterprise Group (三九企業集團), general manager and chairman of Shandong San Jiu Industrial Limited (山東三九實業有限公司), chairman of Shandong San Jiu Pharmaceutical Limited (山東三九藥業有限公司), general manager of San Jiu Enterprise Group (Shenzhen South Pharmaceutical Factory) (三九企業集團 (深圳南方制藥廠)), deputy operation director and general manager of asset management division II and legal risk control department, deputy general manager, general manager, chairman of China Resources Asset Management Limited (華潤資產管理有限公司) and chairman of China Resources Shenzhen International Investment Co., Ltd. (華潤深國投投資有限公司). Mr. ZHANG holds a bachelor's degree in medicine from The Second Military Medical University in the People's Republic of China (中國人民解放軍第二軍醫大學) and a master's degree in business administration from the Guanghua School of Management from Peking University (北京大學光華管理學院) in the People's Republic of China.

was appointed as a non-executive Director in April 2024. Mr. LIN served as the vice president and the chief financial officer in China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (華潤三九醫藥股份有限公司) (a company listed on the Shenzhen Stock Exchange (stock code: 000999)) from August 2011 to July 2018. He worked in the finance department of CR Holdings from July 2018 to August 2021, with his last position as a deputy general manager. Mr. LIN has been a designated external director of the business unit of CR Group since August 2021 including serving as an external director of China Resources Capital Holdings Company Limited (華潤金融控股有限公司) since November 2021, a non-executive director of China Resources Pharmaceutical Group Limited (華潤醫藥集團有限公司) (a company listed on the Stock Exchange (stock code: 3320)) from September 2021 to December 2023, and a director of China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600062)) from October 2023 to December 2025. Mr. LIN holds a master's degree majoring in business and administration from University of South Australia in Australia.

was appointed as a non-executive Director in April 2024. Mr. XIAO served as the deputy manager of the legal department of China Resources Company Limited (中國華潤有限公司) from August 1996 to September 2000. He started to work in China Resources Petrochemical (Group) Co., Ltd. (華潤石化(集團)有限公司) from September 2000 and held several positions including an assistant manager of investment development department from September 2001 to September 2002, a manager of investment development department from October 2002 to February 2004, and a senior manager of investment development department from February 2004 to June 2007. Mr. XIAO then held several positions in CR Chemical (formerly known as China Resources Chemical Holdings Co., Ltd. (華潤化工控股有限公司) and its subsidiaries, including the assistant to general manager and a legal director. Mr. XIAO then served as the deputy general manager of CR Chemical from April 2020 to August 2022. Mr. XIAO has served as a director of China Resources Microelectronics Limited (華潤微電子有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 688396)) since November 2022 and a director of China Resources Digital Technology Holdings Co., Limited (華潤數科控股有限公司) since December 2022. Mr. XIAO holds a master's degree majoring in business administration from Xiamen University (廈門大學) in the People's Republic of China.

has been a Director since December 2025. Mr. Wang has over 34 years of experience in the food and beverage industry, specializing in brand management, marketing strategy, and general management. He served as general manager of the beverage marketing center at Jinmailang Foods Co., Ltd. (今麥郎食品股份有限公司) from 2022 to 2024. From 2001 to 2022, he held various senior roles at Tingyi (Cayman Islands) Holding Corp. (Master Kong) (康師傅控股有限公司), including vice president of group marketing office, vice president of beverage marketing, and special assistant to the chairman. Mr. WANG holds an MBA degree from Soochow University and a BBA degree from National Taiwan University.

has been a Director since August 2022. Dr. ZHAO served as a lawyer in Zhonglun Law Firm from December 2010 to June 2016. He worked as a vice president in the equity investment platform of Zhong Ou Asset Management Company Limited (中歐基金管理有限公司) from June 2016 to August 2020. After that, he has served in Plateau Consumer Fund, L.P.. Dr. ZHAO holds a doctoral degree majoring in civil and commercial law from the Graduate School of Chinese Academy of Social Sciences (中國社會科學院研究生院) in the PRC. Dr. ZHAO obtained the PRC legal professional qualification in March 2012.

was appointed as our independent non-executive Director in October 2024. Dr. CHOW is a solicitor and admitted to practice in Hong Kong and England & Wales and a China-Appointed Attesting Officer (中國司法部委任的中國委託公證人). Dr. CHOW established the law firm Anthony W.K, Chow & Co. (周永健律師行) in September 1982 which has since become Guantao and Chow Solicitors and Notaries (觀韜律師事務所(香港)) of which he is the Senior Consultant (資深顧問). Dr. CHOW served as an independent non-executive director of MTR Corporation Limited (香港鐵路有限公司) (a company listed on the Stock Exchange (stock code: 0066)) from May 2016 to May 2022, and an independent non-executive director of S.F. Holding Co., Ltd. (順豐控股股份有限公司) (a company listed on the Shenzhen Stock Exchange (stock code: 002352)) from December 2016 to December 2022. Dr. CHOW currently serves as director of a number of listed companies, including: (i) a non-executive director of the Kingmaker Footwear Holdings Limited (信星鞋業集團有限公司) (a company listed on the Stock Exchange (stock code: 1170)) since June 1994, (ii) an independent non-executive director of Ping An Healthcare and Technology Company Limited (平安健康醫療科技有限公司) (a company listed on the Stock Exchange (stock code: 1833)) since May 2018, (iii) an independent non-executive director of Beijing North Star Company Limited (北京北辰實業股份有限公司) (a company listed on the Stock Exchange (stock code: 588) and the Shanghai Stock Exchange (stock code: 601588)) since May 2021, and (iv) an independent non-executive director of OneConnect Financial Technology Co., Ltd (壹賬通金融科技有限公司) since October 2020. Dr. CHOW was a Member of The National Committee of the Chinese People's Political Consultative Conference, for four sessions covering 20 years from 2003 to 2023. Dr. CHOW served as the President of The Law Society of Hong Kong from 1997 to 2000, Chairman of the Process Review Panel for the SFC from 2006 to 2012, Chairman of Process Review Panel for the Financial Reporting Council from 2015 to 2020, and Chairman of The Hong Kong Jockey Club from 2018 to 2020. Dr. CHOW was awarded the Justice of the Peace in 1998 and the Silver Bauhinia Star (香港特別行政區銀紫荊星章) in 2003 by the Government of Hong Kong Special Administrative Region. He was admitted to the Honorary Fellowship (榮譽院士) of the Hong Kong Institute of Education (香港教育學院) in March 2010, the Honorary Fellowship (榮譽院士) of King's College London in July 2013, and the Roll of Honour of The Law Society of Hong Kong in 2015. Dr. CHOW was awarded a doctoral degree in social sciences honoris causa from Hong Kong Metropolitan University (香港都會大學) (formerly known as the Open University of Hong Kong (香港公開大學)) in Hong Kong in December 2018 and a doctoral degree of law honoris causa from the Hong Kong University of Science and Technology (香港科技大學) in Hong Kong in November 2021.

was appointed as an independent non-executive Director of the Company in October 2024. Mr. LI served respectively as (i) the general manager of financial department, chief financial officer and vice president of China Merchants Group Limited (招商局集團有限公司), (ii) a chief executive officer of China Merchants Capital Investment Co., Ltd. (招商局資本投資有限責任公司), (iii) a director of China Merchants Port Holdings Company Limited (招商局港口控股有限公司) (formerly known as China Merchants Holdings (International) Company Limited (招商局國際有限公司)) (a company listed on the Stock Exchange (stock code: 144)), (iv) a director of China Merchants Bank Co., Ltd. (招商銀行股份有限公司) (a company listed on the Stock Exchange (stock code: 3968) and the Shanghai Stock Exchange (stock code: 600036)), and (v) a director of China Merchants China Direct Investments Limited (招商局中國基金有限公司) (a company listed on the Stock Exchange (stock code: 133)) from March 2000 to December 2017. Concurrently, Mr. LI also served as directors of a number of other listed companies, including an independent non-executive director of Sound Group Inc. (a company listed on NASDAQ (ticker: SOGP) (formerly known as Lizhi Inc.) from January 2020 to June 2021, an independent non-executive director of Kimou Environmental Holding Limited (金茂源環保控股有限公司) (a company listed on the Stock Exchange (stock code: 6805)) from June 2019 to December 2022, and an independent non-executive director of China AgriProducts Exchange Limited (中國農產品交易有限公司) (a company listed on the Stock Exchange (stock code: 149)) from April 2024 to August 2024. Mr. LI has currently served as directors of a number of listed companies, including: (i) an independent non-executive director of Genertec Universal Medical Group Company Limited (通用環球醫療集團有限公司) (formerly known as Universal Medical Financial and Technical Advisory Services Company Limited (環球醫療金融與技術諮詢服務有限公司)) (a company listed on the Stock Exchange (stock code: 2666)) since June 2015, (ii) an independent non-executive director of Million Cities Holdings Limited (萬城控股有限公司) (a company listed on the Stock Exchange (stock code: 2892)) since June 2018, (iii) an independent non-executive director of Hong Kong Shanghai Alliance Holdings Limited (滬港聯合控股有限公司) (a company listed on the Stock Exchange (stock code: 1001)) since July 2018, (iv) an independent non-executive director of China Everbright Bank Company Limited (中國光大銀行股份有限公司) (a company listed on the Stock Exchange (stock code: 6818) and the Shanghai Stock Exchange (stock code: 601818)) since June 2020, and (v) an independent non-executive director of Mainland Headwear Holdings Limited (飛達帽業控股有限公司) (a company listed on the Stock Exchange (stock code: 1100)) since September 2023. Throughout the significant years of directorship in certain Hong Kong listed companies, Mr. LI has gained relevant experience in, including but not limited to, (i) the review and preparation of comparable and/or audited financial statements of Hong Kong listed companies; (ii) the review of internal control systems; and (iii) the analysis of financial statements and information of Hong Kong listed companies. Moreover, Mr. LI has also obtained vast experience in collaborating and dealing with internal and external auditors regarding the supervision of internal financial controls and the auditing of financial statements. Mr. LI holds a master's degree in economics from Research Institute of Finance of the People's Bank of China (中國人民銀行金融研究所) in the PRC and a master's degree in banking and finance for development from Finafrica Institute in Italy. Mr. LI was qualified as a senior economist of the PRC.

was appointed as an independent non-executive Director of the Company in October 2024. Dr. YAO currently serves as Professor and Dean of Dishui Lake Advanced Finance Institute of Shanghai University of Finance and Economics (上海财经大学滴水湖高级金融学院), and as Adjunct Professor of Peking University (北京大学客座教授). He is the founding editor-in-chief of China Economic Quarterly (《经济学（季刊）》), president of the National Economics Foundation (当代经济学基金会), a member of the Chinese Economists 50 Forum (中国经济50人论坛), and Chairman of the Supervisory Board of China Finance 40 Forum (中国金融40人论坛监事会主席). Dr. YAO has served as deputy dean of the National School of Development of Peking University (北京大学国家发展研究院) since October 2008, and as dean of the National School of Development of Peking University (北京大学国家发展研究院) from November 2012 to January 2024. He served as president of China Annual Economic Meetings (中国经济学年会) from December 2020 to December 2025. He has served as Professor and Dean of Dishui Lake Advanced Finance Institute of Shanghai University of Finance and Economics (上海财经大学滴水湖高级金融学院) since July 2025. Dr. YAO has been awarded the Sun Yefang Award in Economic Sciences (孙冶方经济科学奖) in 2008 and 2014, the First and Second Pushan Awards in International Economics (浦山国际经济学奖) in 2008 and 2010, respectively, and the Second Zhang Peigang Development Economics Award (张培刚发展经济学奖) in 2008. His current major research areas include new political economy, financial development, and political philosophy. Dr. YAO holds a master's degree in economics from Peking University (北京大学) and a doctoral degree in development economics from the University of Wisconsin-Madison (美国威斯康辛大学麦迪逊分校) in the United States.

was appointed as our independent non-executive Director in October 2024. Ms. CHENG served as a consultant in the business consulting division of Arthur Andersen & Co (安達信會計師事務所) from September 1994 to May 1997. She worked in the investment banking arms of DBS Asia Capital Limited (星展亞洲融資有限公司), The Hongkong and Shanghai Banking Corporation Limited (香港上海滙豐銀行有限公司) and Macquarie Group (麥格理集團) from May 1997 to August 2010, with her last position as a division director in Macquarie Capital Securities Limited (麥格理資本證券有限公司). Ms. CHENG joined the global wealth management division of UBS AG (瑞士銀行) as head of corporate advisory group in Hong Kong in September 2010, and subsequently had served there until January 2020 with her last position as a managing director. Ms. CHENG served as the chief financial officer since January 2020 and an executive director since April 2020 in Crazy Sports Group Limited (瘋狂體育集團有限公司) (formerly known as V1 Group Limited (第一視頻集團有限公司)) (a company listed on the Stock Exchange (stock code: 82)) until November 2023. Ms. CHENG has served as the director of development of The Hong Kong Philharmonic Society Limited (香港管弦協會有限公司) since August 2024. Ms. CHENG has served as an independent non-executive director of Zhongsheng Group Holdings Limited (中升集團控股有限公司) (a company listed on the Stock Exchange, stock code: 881) since April 8, 2025. Ms. CHENG is a Fellow of CPA Australia and a Member of American Institute of Certified Public Accountants. She holds a bachelor degree in business administration from The University of Hong Kong (香港大學).